Objective To investigate the clinicopathological features,diagnosis and treatment experience,in order to improve the recognition of male breast cancer and prepare for the study of standardized treatment of breast cancer.Methods Data of epidemiological characteristics,clinical and pathological parameters,treatment and outcome from 43 male breast cancer patients were collected and analyzed in Peking University Cancer Hospital and Beijing Hospital from January 2009 to December 2014.Results Of these patients,42 (97.6％) cases presented with located tumors,11 (25.5％) cases were on pathological stage Ⅲ or stage Ⅳ,and 40 (93.0％) cases were with hormone receptor positive breast cancer and 3 (6.9％) cases were with human epidermal growth factor receptors (HER)-2 positive breast cancer.Patients were stratified according to more or less than 70 years of age,and there were no significant differences in clinicopathological features between the two year groups.But 3 cases with HER-2 over-expressed were all less than 70 years old.38 (88.4％) patients underwent surgical treatment,among which 32 HR-positive patients (74.4％) received tamoxifen as adjuvant endocrine therapy.The median follow-up periods was 31 months (6.1-55.4 months),7 (16.3％) patients developed local recurrence or distant metastasis.Conclusions Male breast cancer is often diagnosed at a later stage and has inferior outcome.Majority of male breast cancer are found to be HR positive,hence hormonal therapy should be strongly considered.%目的 分析男性乳腺癌患者的临床病理特征和诊治经验. 方法 收集北京肿瘤医院及北京医院2009年至2014年收治的43例男性乳腺癌患者资料,分析其流行病学特点、临床表现、病理特征以及治疗方法. 结果 本组患者42例(97.6％)以乳腺肿块起病,Ⅰ期和Ⅱ期患者为32例(74.5％),Ⅲ期和Ⅳ期患者为11例(25.5％).40例(93,0％)患者雌激素受体阳性,3例(6.9％)患者人表皮生长因子受体2(HER-2)过表达.以年龄70岁分层,大于70岁和小于70岁患者临床病理特征无差异,但3例HER-2过表达患者均小于70岁.手术治疗患者占38例(88.4％),其中雌激素受体阳性接受他莫昔芬辅助内分泌治疗患者32例(74.4％).随访时间6.1～55.4个月,中位随访时间31个月,7例(16.3％)患者出现复发转移. 结论 男性乳腺癌确诊时分期较晚,预后较差.大多数患者雌激素受体阳性,内分泌治疗具有重要作用.
展开▼
